Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanoparticles and Their Influence on Organs through the Gut–Organ Axis:...
share announcement

Nanoparticles and Their Influence on Organs through the Gut–Organ Axis: Innovations in Drug Delivery and Gut Microbiota Metabolites

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1427

Special Issue Editors

Dr. Yang-Bao Miao

E-Mail Website
Guest Editor
1. College of Life Science and Technology, University of Electronic Science & Technology of China, Chengdu 610000, China
2. Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu 610000, China
Interests: oral drug delivery; gut to brain; biomaterials; brain disease
Dr. Zhicheng Le

E-Mail Website
Guest Editor
Department of Biomedical Engineering, National University of Singapore, Singapore 117583, Singapore
Interests: microneedles; drug delivery; hydrogels; protein delivery
Prof. Dr. Sanjun Shi

E-Mail Website
Guest Editor
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China
Interests: drug delivery; nanoparticle; nanodrug delivery systems; tumor environment

Special Issue Information

Dear Colleagues,

We are pleased to invite you to explore the specialized realm of nanoscale particles and their profound influence on organs through the intricate gut–organ axis. The unique properties and size of nanoparticles have propelled their status as promising agents for revolutionizing drug delivery techniques. This Special Issue aims to illuminate innovative paths through which nanoparticles traverse the gut–organ axis, showcasing their potential to optimize drug distribution and targeting across diverse organ systems. Additionally, it investigates the symbiotic relationship between nanoparticles and gut microbiota metabolites, revealing an intriguing interplay that holds promise for therapeutic advancements. Our objective is to delve into these dynamic interactions, unraveling novel insights and facilitating future breakthroughs in medicine and biomedical research.

This Special Issue aims to meticulously explore the transformative potential of nanoscale particles within the context of the gut–organ axis. Its objective is to elucidate the pivotal role of nanoparticles in advancing oral drug delivery techniques and comprehending the intricate interplay between nanoparticles and gut microbiota metabolites.

In this Special Issue, original research articles and reviews are welcome. Research areas include, but are not limited to, the following: investigations into nanoparticle-based drug delivery systems via oral delivery, their impact on various organ systems, and their intricate interplay with gut microbiota metabolites. We encourage contributions that deepen our understanding of these interactions, thus fostering advancements in medicine and biomedical research.

We look forward to receiving your contributions.

Dr. Yang-Bao Miao
Dr. Zhicheng Le
Prof. Dr. Sanjun Shi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • biomaterials
  • gut–organ axis
  • gut microbe
  • gut microbiota metabolites

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 5917 KiB  
Article
The Mechanism and Potential Therapeutic Effects of Cyclosporin, Cyclophilin, Probiotics and Syndecan-1 in an Animal Model of Inflammatory Bowel Disease
by Laura Dosh, Francesca Rappa, Abdo Jurjus, Gaelle Karam, Roaa Lezeik, Jad El Masri, Fabio Bucchieri, Angelo Leone and Rosalyn Jurjus
Pharmaceutics 2024, 16(1), 130; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics16010130 - 19 Jan 2024
Viewed by 919
Abstract
Background: Inflammatory bowel diseases (IBDs) have several treatment modalities including immunoregulators, like cyclosporine A, an immunosuppressant that interacts with cytoplasmic cyclophilin A, and probiotics. Aims: This study explored and compared the possible role of syndecan-1 in the IBD pathogenic process as well as [...] Read more.
Background: Inflammatory bowel diseases (IBDs) have several treatment modalities including immunoregulators, like cyclosporine A, an immunosuppressant that interacts with cytoplasmic cyclophilin A, and probiotics. Aims: This study explored and compared the possible role of syndecan-1 in the IBD pathogenic process as well as the effectiveness of cyclophilin A, cyclosporine A, and their combination in the management of IBDs in the presence of probiotics. Methodology: IBD was induced in a total of 112 mice equally divided between syndecan-1 knock-out (KO) and Balb/c wild-type mice, using 2% dextran sulfate sodium (DSS) followed by intraperitoneal treatment with cyclosporine A, cyclophilin A, or a combination of both. In addition, a daily dose of probiotics was given in their drinking water. The animals were monitored for clinical signs and symptoms and checked for gross pathologies in the abdomen after 3 weeks. Descending and sigmoid colon biopsies were collected and fixed for routine microscopy or frozen for protein extraction and molecular testing for IL-6, CD3, CD147, and beta 1 integrins as well as pAkt expression. Results: The data showed that the induction of IBD in the syndecan-1 KO mice was more severe at the clinical, histological, and molecular levels than in the wild type. The combined CypA-CyA treatment showed no added inhibitory effect compared to single-drug treatment in both strains. Probiotics added to the combination was more effective in the wild type and, when used alone, its inhibition of IL-6 was the highest. As for the CD147 marker, there were more suppressions across the various groups in the KO mice except for the probiotics-alone group. Concerning CD3, it was significantly increased by the CypA-CyA complex, which led to more inflammation in the KO mice. Probiotics had little effect with the combination. In relation to beta 1 integrins, the CypA-CyA combination made no significant difference from CyA alone, and adding probiotics to the combination resulted in higher beta 1 integrin expression in the KO mice. As for pAkt, it was very well expressed and upregulated in both strains treated with DSS, but the effect was much larger in the KO mice. In brief, the CypA-CyA complex showed a decrease in the expression of pAkt, but there was no added effect of both drugs. Probiotics along with the complex had a similar reduction effects in both strains, with a greater effect in the wild-type mice, while probiotics alone led to a similar reduction in pAkt expressions in both strains. Conclusions: The differential effects of CyA, CypA, probiotics, and their combinations on the various inflammatory markers, as well as the histological alterations and clinical signs and symptoms, speak in favor of a clear role of syndecan-1 in reducing inflammation. However, probiotics need to be considered after more explorations into the mechanisms involved in the presence of CypA and CyA especially since pAkt is less active in their presence. Full article
(This article belongs to the Special Issue Nanoparticles and Their Influence on Organs through the Gut–Organ Axis: Innovations in Drug Delivery and Gut Microbiota Metabolites)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop